The price of innovation - the role of drug pricing in financing pharmaceutical innovation. A conceptual framework [0.03%]
创新的代价-药品定价在资助药物创新中的作用概念框架
Santiago G Moreno,David Epstein
Santiago G Moreno
The debate on drug prices has reached new heights with the controversy around the role of prices in promoting innovation. Critics claim that prices of innovative drugs are excessive and argue that lowering prices will not harm the flourishi...
President Trump's prescription to reduce drug prices: from the campaign trail to American Patients First [0.03%]
特朗普的降低药价方案：“从竞选承诺到《关怀美国患者第一》”
Monique Dabbous,Clément François,Lylia Chachoua et al.
Monique Dabbous et al.
Background: Drug prices in the United States are the highest in the world, restricting access to the domestic lower income population. President Trump campaigned heavily on promises to reduce drug prices.Methods: A literature review was con...
Disparities of health service for the poor in the coastal area: does Universal health coverage reduce disparities? [0.03%]
沿海地区贫困人群的医疗服务差异：全民医疗能否减少这种差异？
Md Hafiz Iqbal
Md Hafiz Iqbal
Background & Objective: Poor people, in general, get poor quality of health services. The situation is very much worsening for the poor who live in the remote areas in the coastal belt of Bangladesh as health care facilities and services ar...
Estimation of the costs attributable to vitamin K antagonist treatment in patients with non-valvular atrial fibrillation from a French societal perspective [0.03%]
从法国社会角度估算非瓣膜性房颤患者使用维生素K拮抗剂治疗的成本属性费用
Pierre Levy,David Smadja,Julie Dorey et al.
Pierre Levy et al.
Background: Little is known about the costs associated with vitamin K antagonist (VKA) treatment in patients with non-valvular atrial fibrillation (NVAF) in France. Objectives: To evaluate monthly per-patient costs attributable to VKA treat...
Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation [0.03%]
非瓣膜性房颤患者直接口服抗凝药物对比维生素K类似物的现实世界证据的 meta 分析研究
Craig I Coleman,Jean-Baptiste Briere,Laurent Fauchier et al.
Craig I Coleman et al.
Introduction: Numerous real-world studies have compared non-vitamin K antagonist oral anticoagulants (NOACs) with vitamin K antagonists (VKAs) in patients with non-valvular atrial fibrillation (NVAF). A meta-analysis was performed to synthe...
Data collection infrastructure for patient outcomes in the UK - opportunities and challenges for cell and gene therapies launching [0.03%]
英国患者的成果数据收集基础设施——细胞和基因疗法推出的机遇与挑战
Jesper Jørgensen,Laura Mungapen,Panos Kefalas
Jesper Jørgensen
Background: Cell and gene therapies are associated with uncertainty around their value claims at launch due to limitations of supporting clinical data; furthermore, their high costs present affordability issues for payers. Outcomes-based re...
Use of corticosteroids for remission induction therapy in patients with new-onset ulcerative colitis in real-world settings [0.03%]
糖皮质激素诱导新发溃疡性结肠炎临床缓解的现实世界研究
Motohiro Okayasu,Haruhiko Ogata,Yuji Yoshiyama
Motohiro Okayasu
Background: Corticosteroids may be temporarily effective for ulcerative colitis (UC), but long-term use increases the risk of adverse drug reactions. Objective: The goal of the study was to examine steroid use in remission induction therapy...
Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs [0.03%]
从付款人角度减少评估新型抗肿瘤药物的不确定性——健康技术评估的观点
Oriol Solà-Morales,Timm Volmer,Lorenzo Mantovani
Oriol Solà-Morales
Reimbursement decisions on new oncology drugs are now often made while uncertainty remains about a drug's risk-benefit profile. One consequence of this is a delay in patient access to valuable new medicines. We share our perspectives on str...
Results and validation of an index to measure health state of patients with depression in automated healthcare databases [0.03%]
用于自动化医疗数据库中抑郁症患者健康状态测量指数的结果及验证研究
François-Xavier Lamy,Bruno Falissard,Clément François et al.
François-Xavier Lamy et al.
Background and objective: A Depressive Health State Index (DHSI) based on 29 parameters routinely collected in an automated healthcare database (AHDB) was developed to evaluate the health state of depressive patients, and its evolution. The...